Indigenous vaccine COVAXIN demonstrates 100 per cent efficacy against severe COVID-19 disease in Phase-3 interim analysis; Shows overall efficacy of 78 per cent
Apr 21, 2021 |
, |
8:04PM |
Indigenous vaccine COVAXIN demonstrates 100 per cent efficacy against severe COVID-19 disease in Phase-3 interim analysis; Shows overall efficacy of 78 per cent
In a statement, the company said, the second interim results showed India’s First COVID-19 Vaccine had demonstrated strong primary efficacy against severe COVID-19 disease. It said, due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 per cent against mild, moderate, and severe COVID-19 disease.